Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Where Can You Report your Adverse Drug Reactions or Adverse Events Following Immunization

 
Where Can You Report your Adverse Drug Reactions or Adverse Events Following Immunization
 

This section provides a comprehensive overview of the procedures and tools available to Healthcare Professionals, Market Authorization Holders and the General Public to report adverse events associated with medicinal products and vaccines in Lebanon.
 
How to report

You can send the case reports using the following tools:
 
  1. For Healthcare Professionals and the Public
The Lebanese National Pharmacovigilance Program has adapted two user-friendly tools: one for Adverse Drug Reactions (Vigimobile e-Reporting e-Form) and another for reporting Adverse Events Following Immunization (Vigimobile e-Form). Both tools may be accessed by healthcare professionals and the general public.
 
  1. The VigiMobile e-Form and e-Reporting e-Form:
The VigiMobile e-Form and e-Reporting e-Form are the latest tools launched in January 2025 by the Lebanese National Pharmacovigilance Program. These digital platforms were introduced to enhance the reporting process, with the e-Reporting e-Form designed for Adverse Drug Reactions (ADRs) and the VigiMobile e-Form specifically for Adverse Events Following Immunization (AEFIs).

How to Download on Android Phones
 
  1. Scan the QR Code by pressing the link
  2. Click the three dots in the top-right corner
  3. Choose Install app
  4. VigiMobile e-Form/e-Reporting e-Form now appears as an app
 
How to Download on Apple IOS Phones
 
  1. Scan the QR Code by pressing the link
  2. Click on the share button
  3. Add VigiMobile to the home screen
  4. VigiMobile e-Form/e-Reporting e-Form now appears as an app

How to Download on Windows
  1. Press on the link
  2. Install from the Browser menu
  3. VigiMobile e-Form/e-Reporting e-Form is now installed 
 
Scan QR Codes to Report:
  1. ADRs Following Medication Use
  1. AEFIs Following Vaccine Use
Or use the following link: LNPVP: e-Reporting eForm Or use the following link: LNPVP: VigiMobile eForm
 
  1. Direct Contact with the Lebanese National Pharmacovigilance Program:
You may contact the Lebanese National Pharmacovigilance Program through:
  • Email Address:
  • Phone number of the Quality Assurance of Pharmaceutical Products Program: 01-830254   
 
  1.  For Market Authorization Holders:
Based on the Ministerial Resolution MR #181 issued in 2021, MAHs should adhere to the internationally agreed ICH guidelines and standards and send the reports in XML format as specified in ICH E2B (R2 or R3) guidelines

(https://www.moph.gov.lb/userfiles/files/Quality%26Safety/PharmacovigilanceSystemInLebanon/Karar%20181-2021.pdf).

All XML files should be sent to the following emails: pv@moph.gov.lb, and pv.moph@gmail.com.
 
As for what to report or report type, you can refer to Module VI:
https://moph.gov.lb/en/Pages/4/44742/pharmacovigilance-system-lebanon#/en/view/70479/lebanese-guideline-on-good-pharmacovigilance-practices-lgvp-
 
    4
    ...
ATC Name B/G Ingredients Dosage Form Price
N03AX14 LEVETIRACETAM BIOGARAN G Levetiracetam - 1000mg 1000mg Tablet, coated, scored 3,191,626 L.L
C09CA01 LOSARTAN BIOGARAN G Losartan potassium - 100mg 100mg Tablet, coated 439,436 L.L
G04BE30 LIF-DOL B Yohimbin HCl - 3.3mg, Thiamine - 5.5mg, Cyanocobalamine - 0.015mg, Ferrous fumarate - 50mg, Sildenafil citrate - 10mg Tablet, coated 231,653 L.L
C09DA01 LOSARTAN/HYDROCHLOROTHIAZIDE BGR G Losartan potassium - 50mg, Hydrochlorothiazide - 12.5mg Tablet, coated 439,436 L.L
C09DA01 LOSARTAN/HYDROCHLOROTHIAZIDE BGR G Losartan potassium - 100mg, Hydrochlorothiazide - 25mg Tablet, coated 439,436 L.L
J01XX08 LINEZOLIDE STRAGEN G Linezolide - 600mg 600mg Tablet, coated 5,848,403 L.L
J05AF05 LAMIVUDINE ARROW G Lamivudine - 300mg 300mg Tablet, coated 7,850,907 L.L
L02BG04 LETROZOLE ARROW LAB G Letrozole - 2.5mg 2.5mg Tablet, coated 2,000,981 L.L
L02BG04 LETROZOLE BIOGARAN G Letrozole - 2.5mg 2.5mg Tablet, coated 2,402,790 L.L
R03DC03 LUKAST G Montelukast (sodium) - 5mg 5mg Tablet, chewable 783,460 L.L
R03DC03 LUKAST G Montelukast (sodium) - 4mg 4mg Tablet, chewable 783,460 L.L
C09CA01 LOSANET G Losartan potassium - 50mg 50mg Tablet 395,474 L.L
C03CA01 LASIX B Furosemide - 40mg 40mg Tablet 120,946 L.L
R06AX29 LABIXTEN B Bilastine - 20mg 20mg Tablet 584,571 L.L
C09CA01 LOSANET G Losartan potassium - 100mg 100mg Tablet 395,474 L.L
C03CA01 LASIX B Furosemide - 500mg 500mg Tablet 1,454,038 L.L
J01MA12 LEVOMED G Levofloxacin (hemihydrate) - 500mg 500mg Tablet 849,820 L.L
G04BE09 LEVIDOR G Vardenafil (HCl) - 20mg 20mg Tablet 401,809 L.L
G04BE09 LEVIDOR G Vardenafil (HCl) - 5mg 5mg Tablet 876,185 L.L
N05AH02 LEPONEX B Clozapine - 100mg 100mg Tablet 1,975,448 L.L
J01MA14 LOXIMED G Moxifloxacin (HCl) - 400mg 400mg Tablet 851,100 L.L
J01MA14 LOXIPHAR G Moxifloxacin (HCl) - 400mg 400mg Tablet 1,063,555 L.L
N05AH02 LANOLEPT G Clozapine - 100mg 100mg Tablet 1,482,258 L.L
A08AA01 LOMAIRA B Phentermine Hydrochloride - 8mg 8mg Tablet 6,138,673 L.L
C09DA01 LOSANET-H G Losartan potassium - 50mg, Hydrochlorothiazide - 12.5mg Tablet 395,474 L.L
C09DA01 LOSANET-H FORTE G Losartan potassium - 100mg, Hydrochlorothiazide - 12.5mg Tablet 395,474 L.L
R03DC03 LEUKOTRIS G Montelukast - 10mg 10mg Tablet 981,645 L.L
C10AB05 LIPAFIB G Fenofibrate - 160mg 160mg Tablet 627,127 L.L
M03BA03 LUMIRELAX B Methocarbamol - 500mg 500mg Tablet 667,890 L.L
R03DC03 LEUKOTRIS G Montelukast - 5mg 5mg Tablet 979,085 L.L
    4
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025